Using whole blood injections to treat plantar fasciitis
Outcomes of Autologous Whole Blood Injection for the Treatment of Plantar: A Randomized Controlled Trial.
This study tests if injecting your own whole blood can help people with chronic plantar fasciitis feel better compared to a placebo injection.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sultan Qaboos University Academic / other |
| Locations | 1 site (Muscat) |
| Trial ID | NCT05589285 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of autologous whole blood injection as a treatment for chronic plantar fasciitis. Participants will receive either the whole blood injection or a sham saline injection, and their symptoms will be monitored over a period of up to 12 months. The study employs a randomized, prospective, single-blinded design, with outcomes assessed using various scales and ultrasound measurements. The goal is to determine if the whole blood injection leads to better symptom resolution compared to the control group.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with chronic plantar fasciitis who have not responded to conservative management for at least 12 weeks.
Not a fit: Patients with conditions such as diabetes, recent infections, or those who have undergone previous heel surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new, effective option for patients suffering from chronic plantar fasciitis.
How similar studies have performed: While the use of whole blood injections is gaining interest, this specific approach for plantar fasciitis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with chronic plantar fasciitis (persistence of symptoms despite 12 weeks of conservative management) * Age: adults patients more than 18 years * Not having responded to primary conservative managements such as rest, shoe insoles, conventional physical therapy, exercise therapy, and nonsteroidal anti-inflammatory drugs (NSAIDs). Exclusion Criteria: 1. Neurological or vascular insufficiencies in the painful heel 2. Osteomyelitis, fracture of the calcaneus 3. Recent infection in the treatment area, history of rheumatic diseases 4. Immunosuppressive therapy or coagulation disturbance and/or therapy, long-term treatment with corticosteroids 5. Previous heel surgery 6. Patient with diabetes mellitus, 7. Pregnancy 8. Received corticosteroid injection 9. Four weeks since the last anaesthetic injection, iontophoresis, ultrasound and 10. electromyostimulation
Where this trial is running
Muscat
- Sultan Qaboos Univeristy Hospital — Muscat, Oman (Recruiting)
Study contacts
- Principal investigator: Wafa Al Baluki — Sultan Qaboos University Hospital
- Study coordinator: Wafa Al Baluki, BSc, MD, FRCSC.
- Email: albaluki@squ.edu.om
- Phone: +968 71 9999 31
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.